InvestSMART

Firebrick Pharma Limited (ASX:FRE)

ALERT: Price-sensitive ASX Announcement for FRE
Current share price for FRE : $0.037 -0.028 (-43.08%)+
Announcement
Release
16 Oct 2025 9:53AM
Price at Release
$0.065
Full Release
download
Summary
Firebrick Pharma Limited, listed on the ASX as FRE, has announced an additional investment from its strategic partner in the Philippines, Pharma Nutria N.A., Inc. (PNAI). The investment involves a placement of 1.2 million shares at $0.085 per share, representing a 31% premium over the previous closing price. This move aims to restore PNAI's stake to over 5% after a recent placement to other investors. PNAI's director, Mr. Paul Santillana, expressed confidence in Firebrick's vision and its product, Nasodine, which is expected to launch in the Philippines in 2026. The investment is seen as a positive signal by Firebrick's board, with expectations of Nasodine's approval in the Philippines next year.
Key Points
  • Firebrick Pharma received additional investment from Philippines partner PNAI.
  • 1.2 million shares placed at $0.085 per share, a 31% premium over the previous price.
  • Investment restores PNAI's stake to over 5% in Firebrick.
  • PNAI supports Firebrick's vision and Nasodine product.
  • Nasodine expected to launch in the Philippines in 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.